Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Related financial report
AMAG similar filings
- 11 Jun 20 Amag Pharmaceuticals Announces Leadership Changes
- 4 Jun 20 Submission of Matters to a Vote of Security Holders
- 21 May 20 Amag Pharmaceuticals Completes Sale of Its Rights to Intrarosa® to Millicent Pharma for Up to $125 Million
- 11 May 20 Amag Pharmaceuticals Announces First Quarter 2020 Financial Results
- 28 Apr 20 AMAG Pharmaceuticals Appoints Scott Myers as President and Chief Executive Officer
- 16 Apr 20 Amag Pharmaceuticals Provides COVID-19 Company Update
- 4 Mar 20 Amag Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Filing view
External links
Exhibit 16.1
May 11, 2020
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by AMAG Pharmaceuticals, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of AMAG Pharmaceuticals, Inc. dated May 8, 2020. We agree with the statements concerning our Firm in such Form 8-K.
Very truly yours,
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
Attachment